In-hospital Outcomes of Septal Myectomy Versus Alcohol Septal Ablation for Hypertrophic Cardiomyopathy with Outflow Tract Obstruction - An Update and Insights from The National Inpatient Sample from 2011-2019

Author:

Inestroza KarlaORCID,Mijares-Rojas IvanORCID,Matute-Martínez Carlos,Ergui Ian,Albosta Michael,Vergara-Sanchez Carlos,Dangl Michael,Hernandez Rafael Jaciel,Ebner Bertrand,Vincent Louis T,Grant Jelani,Maning Jennifer,Alfonso Carlos,Colombo RosarioORCID

Abstract

AbstractBackgroundSeptal Myectomy (SM) and Alcohol Septal Ablation (ASA) improve symptoms in patients with Hypertrophic Cardiomyopathy with outflow tract obstruction (oHCM). However, outcomes data in this population is predominantly from specialized centers.MethodsThe National Inpatient Database was queried from 2011- 2019 for relevant ICD-9 and −10 diagnostic and procedural codes. We compared baseline characteristics and in-hospital outcomes of patients with oHCM who underwent SM vs. ASA. A p-value <0.001 was considered statistically significant.ResultsWe identified 17,245 patients with oHCM who underwent septal reduction therapies, of whom 62.5% underwent SM, and 37.5% underwent ASA. Patients who underwent SM had higher all-cause mortality (OR:2.2 [1.7-2.9]), post-procedure ischemic stroke (OR: 2.4 [1.8-3.2]), acute kidney injury (OR: 1.9 [1.7-2.2]), vascular complications (OR: 4 [2.8-5.7]), ventricular septal defect (OR: 4.6 [3.5-6.1]), cardiogenic shock (OR: 2 [1.5-2.6]), sepsis (OR: 5.2 [3.3-8.1]), and left bundle branch block (OR: 3.2 [2.8-3.7]), compared to ASA. Patients who underwent ASA had higher post-procedure complete heart block (OR: 1.2 [1.1-1.4]), 2nd-degree AV Block (OR: 2 [1.4-3]), right bundle branch block (OR: 6.4 [5.3-7.8]), ventricular tachycardia (OR:2 [1.8-2.3]), supraventricular tachycardia (OR: 1.4 [1.2-1.7]), and more commonly required pacemaker (OR: 1.4 [1.2-1.6]) or implantable cardioverter-defibrillator insertion (OR: 1.3 [1.1-1.5]) (p<0.001 for all) compared to SM.ConclusionsThis nationwide analysis evidenced that patients undergoing SM had higher in-hospital mortality and periprocedural complications than ASA; however, those undergoing ASA had more post-procedure conduction abnormalities and pacemaker or ICD implantation. The implications of these findings warrant further investigation regarding patient selection strategies for these therapies.

Publisher

Cold Spring Harbor Laboratory

Reference22 articles.

1. Clinical Course and Management of Hypertrophic Cardiomyopathy

2. Hypertrophic Cardiomyopathy

3. Teekakirikul P , Zhu W , Huang HC , Fung E . Hypertrophic Cardiomyopathy: An Overview of Genetics and Management. Biomolecules. 2019; 9:878.

4. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator;Heart Rhythm,2021

5. AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Circulation,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3